Fundamental Facts for Evolus Investors

By Chris Stiles • Wednesday, January 18 15:05 • Permanent Link

It's been a great afternoon session for Evolus investors, who saw their shares rise 16.7% to a price of $9.87 per share. At these higher prices, is the company still fairly valued? If you are thinking about investing, make sure to check the company's fundamentals before making a decision.

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The company belongs to the Healthcare sector, which has an average price to earnings (P/E) ratio of 13.21. In contrast, Evolus has a trailing 12 month P/E ratio of -2.0 based on its earnings per share of $-4.83.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.